Introduction
Patients and methods
Study population and design
Statistical analysis
Results
Variables | All (n:1140) | Male (n:646) | Female (n:494) | p value |
---|---|---|---|---|
Age, years | 60 (42–70) | 61 (47–71) | 60 (35–70) | 0.002 |
Child, n (%) | 113 (9.9) | 54 (8.4) | 59 (11.9) | 0.045 |
Diabetes mellitus, n (%) | 263 (23.1) | 183 (28.3) | 80 (16.2) | < 0.001 |
Hypertensive heart disease, n (%) | 454 (39.8) | 274 (42.4) | 180 (36.4) | 0.041 |
Current smoker, n (%) | 57 (5.0) | 26 (4.0) | 31 (6.3) | 0.084 |
Ischemic heart disease, n (%) | 278 (24.4) | 206 (31.9) | 72 (14.5) | < 0.001 |
Heart failure with reduced EF, n (%) | 351 (30.8) | 237 (36.7) | 114 (23.1) | < 0.001 |
Mildly reduced (41–49%) | 59 (5.2) | 33 (5.1) | 26 (5.3) | |
Reduced (≤ 40%) | 292 (25.6) | 204 (31.6) | 88 (17.8) | |
Valvular heart disease, n (%) | 395 (34.6) | 234 (36.2) | 161 (32.6) | 0.555 |
Mild | 170 (14.9) | 104 (16.1) | 66 (13.4) | |
Moderate | 166 (14.6) | 96 (14.9) | 70 (14.2) | |
Severe | 59 (5.2) | 34 (5.3) | 25 (5.1) | |
Rheumatic heart disease, n (%) | 84 (7.4) | 30 (4.6) | 54 (10.9) | < 0.001 |
Congenital heart disease, n (%) | 151 (13.2) | 75 (11.6) | 76 (15.4) | 0.062 |
Pulmonary arterial hypertension, n (%) | 260 (22.8) | 150 (23.2) | 110 (22.3) | 0.745 |
COPD, n (%) | 66 (5.8) | 13 (2.0) | 53 (10.7) | < 0.001 |
Dilated cardiomyopathy, n (%) | 225 (19.7) | 160 (24.8) | 65 (13.2) | < 0.001 |
Constrictive pericarditis, n (%) | 9 (0.8) | 7 (1.1) | 2 (0.4) | 0.173 |
Peripartum cardiomyopathy, n (%) | 21 (1.8) | – | 21 (4.3) | – |
Tuberculosis, n (%) | 202 (17.7) | 104 (16.1) | 98 (19.8) | 0.101 |
Variables | All (n:1140) | Male (n:646) | Female (n:494) | p value |
---|---|---|---|---|
Ejection fraction, % | 60 (40–65) | 55 (35–60) | 60 (55–65) | < 0.001 |
Interventricular septum thickness, mm | 11 (10–14) | 13 (10–14) | 11 (10–14) | 0.001 |
LV diastolic dysfunction and grades, n (%) | 668 (58.6) | 416 (64.4) | 252 (51.0) | < 0.001 |
Grade I | 486 (42.6) | 289 (44.7) | 197 (39.9) | |
Grade II | 141 (12.4) | 99 (15.3) | 42 (8.5) | |
Grade III | 34 (2.9) | 23 (3.6) | 11 (2.2) | |
Grade IV | 7 (0.6) | 5 (0.8) | 2 (0.4) | |
Aortic valve insufficiency, n (%) | 437 (38.3) | 260 (40.2) | 177 (35.8) | 0.233 |
Mild | 340 (29.8) | 209 (32.4) | 131 (26.5) | |
Moderate | 81 (7.1) | 42 (6.5) | 39 (7.9) | |
Severe | 16 (1.4) | 9 (1.4) | 7 (1.4) | |
Aortic valve stenosis, n (%) | 87 (7.6) | 0.118 | ||
Mild | 52 (4.6) | 25 (3.9) | 27 (5.5) | |
Moderate | 9 (0.8) | 5 (0.8) | 4 (0.8) | |
Severe | 26 (2.3) | 20 (3.1) | 6 (1.2) | |
Mitral valve insufficiency, n (%) | 541 (47.5) | 322 (49.8) | 219 (44.3) | 0.135 |
Mild | 263 (23.1) | 150 (23.2) | 113 (22.9) | |
Moderate | 254 (22.3) | 154 (23.8) | 100 (20.2) | |
Severe | 24 (2.1) | 18 (2.8) | 6 (1.2) | |
Mitral valve stenosis, n (%) | 39 (3.4) | 13 (2.0) | 26 (5.3) | 0.003 |
Mild | 18 (1.6) | 9 (1.4) | 9 (1.8) | |
Moderate | 8 (0.7) | 1 (0.2) | 7 (1.4) | |
Severe | 13 (1.1) | 3 (0.5) | 10 (2.0) | |
Tricuspid valve insufficiency, n (%) | 264 (23.2) | 153 (23.7) | 111 (22.5) | 0.880 |
Systolic pulmonary artery pressure, mmHg | 20 (15–30) | 22 (15–30) | 18 (20–30) | 0.776 |
Valvular vegetation, n (%) | 2 (0.2) | 1 (0.2) | 1 (0.2) | 0.677 |
Left ventricular thrombus, n (%) | 5 (0.4) | 5 (0.8) | 0 (0) | 0.074 |
Permeant pacemaker lead, n (%) | 6 (0.5) | 5 (0.8) | 1 (0.2) | 0.244 |
Pericardial effusion, n (%) | 125 (10.9) | 70 (10.8) | 55 (11.1) | 0.326 |
Mild | 114 (10.0) | 65 (10.1) | 49 (9.9) | |
Moderate | 8 (0.7) | 4 (0.6) | 4 (0.8) | |
Severe | 3 (0.3) | 1 (0.2) | 2 (0.4) |
Age category, years | Non-compaction n (%) | ASD n (%) | AVCD n (%) | PDA n (%) | Congenital PS n (%) | Dextrocardia n (%) | ToF n (%) | HCMP n (%) | Myxoma n (%) | TGA n (%) | VSD n (%) | Subaortic membrane n (%) | Percentage among CHDs, n (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0–15 | 0 (0) | 25 (2.2) | 5 (0.4) | 23 (2.0) | 7 (0.6) | 0 (0) | 15 (1.3) | 0 (0) | 0 (0) | 8 (0.7) | 18 (1.6) | 1 (0.1) | 102 (67.5) |
16–30 | 1 (0.1) | 8 (0.7) | 1 (0.1) | 2 (0.2) | 3 (0.3) | 0 (0) | 4 (0.4) | 4 (0.4) | 0 (0) | 0 (0) | 5 (0.4) | 1 (0.1) | 29 (19.2) |
31–45 | 0 (0) | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.1) | 1 (0.1) | 1 (0.1) | 0 (0) | 2 (0.2) | 0 (0) | 6 (4.0) |
46–60 | 3 (0.3) | 2 (0.2) | 0 (0) | 0 (0) | 0 (0) | 1 (0.1) | 0 (0) | 4 (0.4) | 1 (0.1) | 0 (0) | 1 (0.1) | 0 (0) | 12 (7.9) |
61–75 | 1 (0.1) | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (1.3) |
+ 75 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Percentage among the study population | 5 (0.4) | 37 (3.2) | 6 (0.5) | 25 (2.2) | 10 (0.9) | 1 (0.1) | 20 (1.8) | 9 (0.8) | 2 (0.2) | 8 (0.7) | 26 (2.3) | 2 (0.2) |